Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H24F2N2O3 |
Molecular Weight | 390.4237 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)COCCN1CCN(CC1)C(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3
InChI
InChIKey=BAWMMJAUVBLLEE-UHFFFAOYSA-N
InChI=1S/C21H24F2N2O3/c22-18-5-1-16(2-6-18)21(17-3-7-19(23)8-4-17)25-11-9-24(10-12-25)13-14-28-15-20(26)27/h1-8,21H,9-15H2,(H,26,27)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11829715Curator's Comment: description was created based on several sources, including:
http://www.pharmacodia.com/yaodu/html/v1/chemicals/9c3368c58b7c3569a3e83048cfc8d023.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11829715
Curator's Comment: description was created based on several sources, including:
http://www.pharmacodia.com/yaodu/html/v1/chemicals/9c3368c58b7c3569a3e83048cfc8d023.html
Efletirizine is histamine H1 receptor antagonist. Restricted to topical use. It was under investigation in Phase III (in Europe) clinical studies for the treatment of allergic rhinitis and chronic idiopathic urticarial. Research was discontinued in 2005 due to limited clinical efficacy and safety data. Efletirizine also reduced ocular itching.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11829715 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Quantitation of efletirizine in human plasma and urine using automated solid-phase extraction and column-switching high-performance liquid chromatography. | 1999 Jul 9 |
|
Antihistamines in late-phase clinical development for allergic disease. | 2002 Feb |
|
Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. | 2004 Nov 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11829715
15, 30 and 60 ug/100 ul (0.15%, 0.3% or 0.6%) twice-daily for two weeks
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
150756-35-7
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
SUB06467MIG
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
C73048
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
DTXSID50164606
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
C121361
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
7221
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
66003
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104290
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
100000080535
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY | |||
|
B6C301298G
Created by
admin on Fri Dec 15 16:19:28 GMT 2023 , Edited by admin on Fri Dec 15 16:19:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)